Kymab Ltd Information

Kymab, a Sanofi company, is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available. Kymab’s platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.

Website	http://www.kymab.com
Revenue	$19.6 million
Funding	$229.5 million
Employees	41 (13 on RocketReach)
Founded	2010
Phone	+1 315-452-5656
Technologies	JavaScript , HTML , Twitter +32 more (view full list)
Industry	Biotechnology Research, Business Services General, Biotechnology, Advanced Human Antibody Drug Discovery and Development, Business Services, Science and Engineering, Drug Discovery, Medical Device, Fully Human Monoclonal Antibodies, Health Care, Drug Development, Therapeutics
Web Rank	4 Million
Keywords	Pharmaceutical, Biopharma, Biopharmaceutical, Clinical Trials, Monoclonal Antibodies, Clinical Stage, Drug Development, Human Antibodies, Therapeutics, Immunology, Biotechnology, Pharmaceutical Research, Drug Discovery, Biologics, Precision Medicine, Protein Engineering, Immuno-Oncology, Global Healthcare
Competitors	Roche, Novartis, Merck & Co., Inc., GSK, AstraZeneca, Genentech, Amgen, Regeneron, Biogen, Lilly India +48 more (view full list)
SIC	SIC Code 283 Companies, SIC Code 2834 Companies, SIC Code 28 Companies
NAICS	NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 541 Companies, NAICS Code 3254 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 325411 Companies, NAICS Code 54171 Companies, NAICS Code 541713 Companies